Opus Genetics Highlights Advancing Inherited Retinal Disease Pipeline
I'm LongbridgeAI, I can summarize articles.Opus Genetics (IRD) hosted a virtual R&D Science Forum on June 16, 2026, highlighting its fully funded pipeline for five inherited retinal disease programs targeting RDH12, MERTK, RHO, LCA5, and BEST1. The company emphasized a portfolio approach for cost-effective development. Analyst ratings vary, with one Buy at $16.00 and TipRanks' AI Spark assigning a Neutral rating due to weak financials despite added funding capacity.
Opus Genetics ( (IRD) ) has shared an update.
On June 16, 2026, Opus Genetics hosted a virtual R&D Science Forum at which management and external key opinion leaders presented an overview of the company’s clinical pipeline in inherited retinal diseases. The event, available by webcast, highlighted programs targeting RDH12, MERTK, RHO, LCA5 and BEST1, as well as Opus’s broader clinical development strategy, IRD patient journey and recruitment efforts.
The forum underscored Opus’s fully funded position to advance five IRD clinical programs, emphasizing a portfolio approach designed to generate multiple data readouts and milestones. Management framed these gene therapy candidates as follow-on treatments to the first approved IRD gene therapy, aiming for cost‑effective development with compelling economics and reinforcing the company’s positioning in the competitive retinal gene therapy space.
The most recent analyst rating on (IRD) stock is a Buy
with a $16.00 price target.
To see the full list of analyst forecasts on Opus Genetics stock,
see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
The score is held back primarily by weak financial performance (heavy losses, negative equity, and cash burn). Technicals are neutral-to-moderate with longer-term improvement but limited near-term momentum, while valuation is constrained by ongoing losses and no dividend. Corporate events modestly help via added funding capacity, though with leverage and dilution considerations.
To see Spark’s full report on IRD stock,
click here.
More about Opus Genetics
Opus Genetics, Inc. is a clinical-stage biotechnology company focused on gene therapies for inherited retinal diseases (IRDs). The company is advancing a portfolio of five IRD clinical programs that build on experience from the first approved IRD gene therapy, supported by broad intellectual property protection and eligibility for orphan drug exclusivity.
Average Trading Volume: 811,362
Technical Sentiment Signal: Hold
Current Market Cap: $328.8M